Tampa, FL (Feb. 7, 2008) – Several Moffitt Cancer Center physicians will present new research at the 2008 BMT Tandem Meetings, a joint effort between the Center for International Blood & Marrow Transplant Research and the American Society for Blood and Marrow Transplantation.
This year’s BMT Tandem Meetings will be Feb. 13 through 17 at the Manchester Grand Hyatt in San Diego.
Among Moffitt’s BMT faculty who will present are:
About Moffitt Cancer Center Located in Tampa, Florida, Moffitt Cancer Center (www.moffitt.org) is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer, as well as for ear, nose and throat. Moffitt’s sole mission is to contribute to the prevention and cure of cancer. ###
- Melissa Alsina on the use of Bortezomib plus high-dose Melphalan and autologous stem cell rescue as an effective treatment for patients with Primary Refractory Multiple Myeloma.
- Ernesto Ayala on a meta-analysis showing that high dose chemotherapy and autologous stem cell rescue is better than standard dose therapy to control follicular lymphoma.
- Hugo Fernandez on the use of allogeneic stem cell transplants for patients older than 60 with acute myeloid leukemia and myelodysplastic syndrome. Results have demonstrated median survival outcomes of more than one year, better than what has been reported previously in this age group with standard chemotherapy.
- William Janssen on intraprocedural sampling used to accurately determine final aphaeresis volume for hematopoietic progenitor cell collection.
- Mohamed Kharfan-Dabaja on the safety of Rituximab in patients with lymphoid malignancies undergoing allogeneic hematopoietic cell transplantation.
- Janelle Perkins on Voriconazole as an effective prophylaxis for Aspergillus invasive fungal infection in patients receiving glucocorticosteroid therapy for graft-versus-host disease after allogeneic transplantation.
- Xue-Zhong Yu on targeting 2 integrins to alleviate graft-versus-host disease and spare graft-versus-leukemia effect activity after allogeneic BMT in mice.